+46.1%
GSK vs ULTA
+28.6%
+17.5%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | ULTA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.0% | -1.1% | +0.1% | -0.9% |
| 7D | -5.4% | -3.9% | -1.6% | -5.0% |
| 30D | -4.6% | -1.1% | -3.6% | -4.6% |
| 3M | -5.1% | +13.8% | -18.9% | -6.4% |
| 6M | -11.4% | -17.2% | +5.8% | -10.1% |
| YTD | +0.7% | -11.5% | +12.2% | +1.6% |
| 1Y | +23.0% | +3.9% | +19.1% | +22.2% |
| All | +46.1% | +28.6% | +17.5% | +38.0% |
Cumulative growth
Daily Returns
Daily percentage return beside ULTA.
Daily Out/Under-Performance
Portfolio return minus ULTA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × ULTA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded ULTA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling